THERAPY DOSSIER · th-a1dbec7bc614

Pannexin 1 blockers: 10panx peptide, carbenoxolone and probenecid

Drug · Carbenoxolone: 11-beta-hydroxysteroid dehydrogenase inhibitor; used as a gap-junction/pannexin-1 blocker (INHIBITOR)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Carbenoxolone: 11-beta-hydroxysteroid dehydrogenase inhibitor; used as a gap-junction/pannexin-1 blocker (INHIBITOR)
Target: CHEMBL3542430
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: CHEMBL499915 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Carbenoxolone; probenecid (co-listed); 10panx peptide (co-listed)
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25102401 ↗2014Reported benefit

Pannexin 1: a novel participant in neuropathic pain signaling in the rat spinal cord.

RatOtherSprague-DawleyMaleIntrathecal

Model: Spared nerve injury neuropathic pain model involving sural nerve transection, with sham-operated controls

Sural nerve transection lowered the threshold for C-reflex activation and produced persistent mechanical hypersensitivity to pressure stimuli. Intrathecal administration of the three pannexin 1 blockers significantly depressed spinal C-reflex wind-up activity in both neuropathic and sham rats, and…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…